October 23, 2024
Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups
Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical trials. The conference will include attendees from industry experts to patient groups.
The Outsourcing in Clinical Trials Conference will take place on the 23th-24th October 2024 in Boston, MA. This event will explore the challenges in clinical trials for broad area diseases, like diabetes and leukemia and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com